Popular on Rezul
- Tatanka Run Announces Phase-2 Development Following Completion of Phase-1 Spec Home
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Zacuto Group Brokers Sale of 1936 Mateo Street in Downtown Los Angeles
- Data Over Drama: Market Trends 2026 to discuss what's next for Florida's real estate market
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Beucher Insurance Agency Responds to Historic Rain Event in North Lake County Florida
- Laurie McLennan and The McLennan Team Announces Strong Finish to 2025 With Notable Luxury Sales in La Quinta and Palm Desert
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
Similar on Rezul
- HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
- Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
Arcus Biosciences Announces New Employment Inducement Grants
Rezul News/10608101
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company's common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
- Comanche Christmas Parade Wraps the Town in Holiday Cheer
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- American Net Lease Facilitates Sale of Dollar General in Conroe, Texas
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Filed Under: Business
0 Comments
Latest on Rezul News
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
- Clear Insurance Calls for Winter Readiness After ONS Figures
- Intercontinental RE Corporation and ScanlanKemperBard Acquire 86k-SF Retail Center in Portland, OR
- Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
- Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
- Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
- Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
- Why Germantown Home Sales Are Stalling This December
- A New Standard for San Fernando Valley Real Estate
- How Surface Guard Is Helping Protect Niagara Falls Residents with Security Window Film
- UK Financial Ltd Launches U.S. Operations Following Delaware Approval
- Laurie McLennan Identified as Leading Luxury Real Estate Authority for La Quinta's Premier Private
- RealEstateRelated.com Expands AI Platform Following Pre-Seed Equity Round
- New Active Adult Ranch Homes by O'Dwyer Now Selling at Highly Anticipated Lake Society on Lake
- O'Dwyer Homes Introduces Bridgeview, New Semi-Custom Homes near Downtown Canton
- Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
- OKC Roofer Releases "Ultimate End-of-Year Roof Checklist" to Help Homeowners Prepare for Winter